Schedule a 1:1 partnering meeting with our drug development experts and join us for our happy hour seminar and networking reception at BIO International in June.
Meet with our experts at BIO
Join us for the upcoming BIO International Convention, June 13-16. Our Principal Research Fellow for Drug Substance, Dr. Paul Quigley, and Sr. Drug Development Consultant, Dr. Aruna Railkar, will be participating in partnering meetings to learn more about your drug development needs and to provide an update on our expanded capabilities.
Schedule a meeting with Paul or Aruna in the BIO portal or by emailing us.
Join us for our happy hour seminar
We'll be hosting a complimentary happy hour seminar and networking reception during BIO on Wednesday, June 15 from 4-6:30pm at Roy's. Hear a presentation from Dr. Paul Quigley, "Moving Drug Substance Off the Critical Path- Streamlined Strategies to Accelerate to First-in-Human & Beyond."
In this presentation, Paul will discuss the different routes that drug developers can take to synthesize and manufacture their drug substance and evaluate their pros and cons. He will share how integrated drug substance and drug product capabilities in the candidate selection stage can aid in selecting the best molecules to move forward with into drug substance and beyond.
Using case studies, Paul will demonstrate how drug substance and drug product development plans can be accelerated through innovative science and expertise in order to help you get your program’s drug substance off the critical path. Key technologies that can be employed to establish a robust, and commercially scalable synthetic process will also be reviewed.
About our experts
Dr. Paul Quigley, Principal Research Fellow for Drug Substance
Paul has over 20 years experience in the chemical and pharmaceutical industries in a variety of senior management roles, covering Technical Management of UK Sites, and Senior Project and Operational roles within a number of international organizations including ICI, Schering Plough, Clariant, Johnson Matthey and Rhodia.
Paul graduated with a PhD in Natural Product Chemistry from University College Dublin in 1988 and with an MBA from Warwick Business School in 2000. He has co-authored a number of papers in the areas of Biocatalysis, Organic Synthesis, Polymer Chemistry and Natural Product Chemistry, and has generated several Patents in this area. Paul is a Member of the Royal Society of Chemistry and the Association of MBAs.
Dr. Aruna Railkar, Senior Drug Development Consultant
Dr. Aruna Railkar has over 25 years of experience in the pharmaceutical industry working at the discovery – development interface, providing critical input for progressing compounds into clinical development, prodrug evaluation, understanding challenges in absorption/exposure of lead molecules and development of formulation strategies (conventional or enabling) based on compound properties.
During her career at Hoffmann-La Roche, Aruna led the group characterizing the physicochemical and biopharmaceutic properties of compounds to inform NCE selection and provided stage appropriate formulation development for preclinical and clinical studies collaborating with discovery and development teams in multiple therapeutic areas. Her recent experience also covers clinical formulation development of poorly soluble molecules using amorphous or lipid-based formulations, oral and injectable controlled release dosage forms.
Aruna's area of interest is in the development of novel dosage forms for existing drugs (as an alternate route of administration or improved delivery which can use the 505(b)(2) development pathway). She joined Quotient Sciences as a Senior Research Fellow in the scientific consulting group and supports the Business Development team in designing and scoping the studies for clients and assisting in scientific and technical discussions.